<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36570463</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2295</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in neurology</Title><ISOAbbreviation>Front Neurol</ISOAbbreviation></Journal><ArticleTitle>Investigating neurological symptoms of infectious diseases like COVID-19 leading to a deeper understanding of neurodegenerative disorders such as Parkinson's disease.</ArticleTitle><Pagination><StartPage>968193</StartPage><MedlinePgn>968193</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">968193</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fneur.2022.968193</ELocationID><Abstract><AbstractText>Apart from common respiratory symptoms, neurological symptoms are prevalent among patients with COVID-19. Research has shown that infection with SARS-CoV-2 accelerated alpha-synuclein aggregation, induced Lewy-body-like pathology, caused dopaminergic neuron senescence, and worsened symptoms in patients with Parkinson's disease (PD). In addition, SARS-CoV-2 infection can induce neuroinflammation and facilitate subsequent neurodegeneration in long COVID, and increase individual vulnerability to PD or parkinsonism. These findings suggest that a post-COVID-19 parkinsonism might follow the COVID-19 pandemic. In order to prevent a possible post-COVID-19 parkinsonism, this paper reviewed neurological symptoms and related findings of COVID-19 and related infectious diseases (influenza and prion disease) and neurodegenerative disorders (Alzheimer's disease, PD and amyotrophic lateral sclerosis), and discussed potential mechanisms underlying the neurological symptoms and the relationship between the infectious diseases and the neurodegenerative disorders, as well as the therapeutic and preventive implications in the neurodegenerative disorders. Infections with a relay of microbes (SARS-CoV-2, influenza A viruses, gut bacteria, etc.) and prion-like alpha-synuclein proteins over time may synergize to induce PD. Therefore, a systematic approach that targets these pathogens and the pathogen-induced neuroinflammation and neurodegeneration may provide cures for neurodegenerative disorders. Further, antiviral/antimicrobial drugs, vaccines, immunotherapies and new therapies (e.g., stem cell therapy) need to work together to treat, manage or prevent these disorders. As medical science and technology advances, it is anticipated that better vaccines for SARS-CoV-2 variants, new antiviral/antimicrobial drugs, effective immunotherapies (alpha-synuclein antibodies, vaccines for PD or parkinsonism, etc.), as well as new therapies will be developed and made available in the near future, which will help prevent a possible post-COVID-19 parkinsonism in the 21st century.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Zhang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Washington University in St. Louis, St. Louis, MO, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Neurol</MedlineTA><NlmUniqueID>101546899</NlmUniqueID><ISSNLinking>1664-2295</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">neurodegenerative disorders</Keyword><Keyword MajorTopicYN="N">neurological symptoms</Keyword><Keyword MajorTopicYN="N">post-COVID-19 parkinsonism management and prevention</Keyword></KeywordList><CoiStatement>The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>26</Day><Hour>4</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36570463</ArticleId><ArticleId IdType="pmc">PMC9768197</ArticleId><ArticleId IdType="doi">10.3389/fneur.2022.968193</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. (2021) 8:416&#x2013;27. 10.1016/S2215-0366(21)00084-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(21)00084-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou SHY, Beghi E, Helbok R, Moro E, Sampson J, Altamirano V, et al. . Global incidence of neurological manifestations among patients hospitalized with COVID-19&#x2014;a report for GCS-NeuroCOVID Consortium and the ENERGY Consortium. JAMA Netw Open. (2021) 4:e2112131. 10.1001/jamanetworkopen.2021.12131</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.12131</ArticleId><ArticleId IdType="pmc">PMC8114143</ArticleId><ArticleId IdType="pubmed">33974053</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Miranda-Saksena M, Saksena NK. Viruses and neurodegeneration. Virol J. (2013) 10:172. 10.1186/1743-422X-10-172</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-10-172</ArticleId><ArticleId IdType="pmc">PMC3679988</ArticleId><ArticleId IdType="pubmed">23724961</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki RF. Herpes simplex virus type 1 and Alzheimer's disease: increasing evidence for a major role of the virus. Front Aging Neurosci. (2014) 6:202. 10.3389/fnagi.2014.00202</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2014.00202</ArticleId><ArticleId IdType="pmc">PMC4128394</ArticleId><ArticleId IdType="pubmed">25157230</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang H, Boltzc D, Sturm-Ramirezc K, Shepherda KR, Jiaoa Y, Websterc R, et al. . Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci USA. (2009) 106:14063&#x2013;8. 10.1073/pnas.0900096106</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0900096106</ArticleId><ArticleId IdType="pmc">PMC2729020</ArticleId><ArticleId IdType="pubmed">19667183</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowen LN, Tyagi R, LiW, Alfahad T, Smith B, WrightM, et al. . HIV-associated motor neuron disease: HERV-K activation and response to antiretroviral therapy. Neurology. (2016) 87:1756&#x2013;62. 10.1212/WNL.0000000000003258</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003258</ArticleId><ArticleId IdType="pmc">PMC5089528</ArticleId><ArticleId IdType="pubmed">27664983</ArticleId></ArticleIdList></Reference><Reference><Citation>Pajo AT, Espiritu AI, Apor ADAO, Jamora RDG. Neuropathological findings of patients with COVID-19: a systematic review. Neurol Sci. (2021) 43:1255&#x2013;66. 10.1007/s10072-021-05068-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-021-05068-7</ArticleId><ArticleId IdType="pmc">PMC7822400</ArticleId><ArticleId IdType="pubmed">33483885</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarifkar P, Peinkhofer C, BenrosME, Kondziella D. Frequency of neurological diseases after COVID-19, Influenza A/B and Bacterial Pneumonial. Front Neurol. (2022) 13:904796. 10.3389/fneur.2022.904796</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2022.904796</ArticleId><ArticleId IdType="pmc">PMC9259944</ArticleId><ArticleId IdType="pubmed">35812108</ArticleId></ArticleIdList></Reference><Reference><Citation>Smeyne RJ, Eells J, Chatterjee D, Byrne M, Akula SM, Sriramula S, et al. . COVID-19 infection enhances susceptibility to oxidative stress-induced parkinsonism. Mov Disord. (2022) 37:1394&#x2013;1404. 10.1002/mds.29116</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.29116</ArticleId><ArticleId IdType="pmc">PMC9347874</ArticleId><ArticleId IdType="pubmed">35579496</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Liu J, Lin J, Shang H. COVID-19 and risk of neurodegenerative disorders: a Mendelian randomization study. Transl Psychiatry. (2022) 12:238. 10.1038/s41398-022-02052-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-022-02052-3</ArticleId><ArticleId IdType="pmc">PMC9281279</ArticleId><ArticleId IdType="pubmed">35835752</ArticleId></ArticleIdList></Reference><Reference><Citation>Krey L, Huber MK, Hoglinger GU, Wegner F. Can SARS-CoV-2 infection lead to neurodegeneration and Parkinson's disease? Brain Sci. (2021) 11:1654. 10.3390/brainsci11121654</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11121654</ArticleId><ArticleId IdType="pmc">PMC8699589</ArticleId><ArticleId IdType="pubmed">34942956</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferini-Strambi L, Salsone M. COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable? J Neurol. (2021) 21:1&#x2013;11. 10.1007/s00415-020-10070-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10070-8</ArticleId><ArticleId IdType="pmc">PMC7372546</ArticleId><ArticleId IdType="pubmed">32696341</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. . Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. (2021) 4:e2128568. 10.1001/jamanetworkopen.2021.28568</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayase Y, Tobita K. Influenza virus and neurological diseases. Psychiatry Clin Nerrrosci. (l997) 51:181&#x2013;4. 10.1111/j.1440-1819.1997.tb02580.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1819.1997.tb02580.x</ArticleId><ArticleId IdType="pubmed">9316161</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocoros NM, Svensson E, Szepligeti SK, Vestergaard SV, Szentkuti P, Thomsen RW, et al. . Long-term risk of Parkinson disease following influenza and other infections. JAMA Neurol. (2021) 78:1461&#x2013;70. 10.1001/jamaneurol.2021.3895</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.3895</ArticleId><ArticleId IdType="pmc">PMC8546623</ArticleId><ArticleId IdType="pubmed">34694344</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez-Guerrero A, Laespada-Garcia MI, Gomez-Grande A, Ruiz-Ortiz M, Blanco-Palmero VA, Azcarate-Diaz FJ, et al. . Acute hypokineticrigid syndrome following SARS-CoV-2 infection. Neurology. (2020) 95:e2109&#x2013;118. 10.1212/WNL.0000000000010282</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010282</ArticleId><ArticleId IdType="pubmed">32641525</ArticleId></ArticleIdList></Reference><Reference><Citation>Faber I, Brandao PRP, Menegatti F, de Carvalho Bispo DDD, Maluf FB, Cardoso F. Coronavirus disease 2019 and parkinsonism: a non-post-encephalitic case. Mov Disord. (2020) 35:1721&#x2013;2. 10.1002/mds.28277</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28277</ArticleId><ArticleId IdType="pmc">PMC7461093</ArticleId><ArticleId IdType="pubmed">32815213</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen ME, Eichel R, Steiner-Birmanns B, Janah A, Ioshpa M, Bar-Shalom R, et al. . A case of probable Parkinson's disease after SARS-CoV-2 infection. Lancet Neurol. (2020) 19:804&#x2013;5. 10.1016/S1474-4422(20)30305-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30305-7</ArticleId><ArticleId IdType="pmc">PMC7494295</ArticleId><ArticleId IdType="pubmed">32949534</ArticleId></ArticleIdList></Reference><Reference><Citation>Akilli NB, Yosunkaya A. Part of the Covid-19 puzzle: acute parkinsonism. Am J Emerg Med. (2021) 47:333. e1&#x2013;333.e3. 10.1016/j.ajem.2021.02.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2021.02.050</ArticleId><ArticleId IdType="pmc">PMC7903921</ArticleId><ArticleId IdType="pubmed">33712341</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao AR, Hidayathullah SM, Hegde K, Adhikaria P. Parkinsonism: an emerging post COVID sequelae. IDCases. (2022) 27:e01388. 10.1016/j.idcr.2022.e01388</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idcr.2022.e01388</ArticleId><ArticleId IdType="pmc">PMC8733235</ArticleId><ArticleId IdType="pubmed">35018281</ArticleId></ArticleIdList></Reference><Reference><Citation>Makhoul K, Jankovic J. Parkinson's disease after COVID-19. J Neurol Sci. (2021) 422:117331. 10.1016/j.jns.2021.117331</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.117331</ArticleId><ArticleId IdType="pmc">PMC9755718</ArticleId><ArticleId IdType="pubmed">33540185</ArticleId></ArticleIdList></Reference><Reference><Citation>Morassi M, Palmerini F, Nici S, Magni E, Savelli G, Guerra UP, et al. . SARS-CoV-2-related encephalitis with prominent parkinsonism: clinical and FDG-PET correlates in two patients. J Neurol. (2021) 268:3980&#x2013;7. 10.1007/s00415-021-10560-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10560-3</ArticleId><ArticleId IdType="pmc">PMC8059684</ArticleId><ArticleId IdType="pubmed">33884450</ArticleId></ArticleIdList></Reference><Reference><Citation>Semerdzhiev SA, Fakhree MAA, Segers-Nolten I, Blum C, Claessens MMAE. Interactions between SARS-CoV-2 N-Protein and alpha-Synuclein accelerate amyloid formation. ACS Chem Neurosci. (2022) 13:143&#x2013;50. 10.1021/acschemneuro.1c00666</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.1c00666</ArticleId><ArticleId IdType="pmc">PMC8739828</ArticleId><ArticleId IdType="pubmed">34860005</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Han Y, Yang L Kim T, Nair M, Harschnitz O, et al. . SARSCoV-2 infection causes dopaminergic neuron senescence. Res Sq. (2021) 5.21:rs.3.rs-513461. 10.21203/rs.3.rs-513461/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-513461/v1</ArticleId><ArticleId IdType="pmc">PMC8142658</ArticleId><ArticleId IdType="pubmed">34031650</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubota T, Kuroda N. Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: a systematic review. Clin Neurol Neurosurg. (2021) 200:106349&#x2013;55. 10.1016/j.clineuro.2020.106349</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2020.106349</ArticleId><ArticleId IdType="pmc">PMC7604080</ArticleId><ArticleId IdType="pubmed">33172719</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouali-Benazzouz R, Benazzouz A. COVID-19 infection and parkinsonism: is there a link? Mov Disord. (2021) 36:1737&#x2013;43. 10.1002/mds.28680</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28680</ArticleId><ArticleId IdType="pmc">PMC8242862</ArticleId><ArticleId IdType="pubmed">34080714</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulzer D, Antonini A, Leta V, Nordvig A, Smeyne RJ, Goldman JE, et al. . COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. npj Parkinsons Dis. (2020) 6:18. 10.1038/s41531-020-00123-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-020-00123-0</ArticleId><ArticleId IdType="pmc">PMC7441399</ArticleId><ArticleId IdType="pubmed">32885037</ArticleId></ArticleIdList></Reference><Reference><Citation>Beauchamp LC, Finkelstein DI, Bush AI, Evansd AH, Barnham KJ. Parkinsonism as a third wave of the COVID-19 pandemic? J Parkinsons Dis. (2020) 10:1343&#x2013;53. 10.3233/JPD-202211</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-202211</ArticleId><ArticleId IdType="pmc">PMC7683045</ArticleId><ArticleId IdType="pubmed">32986683</ArticleId></ArticleIdList></Reference><Reference><Citation>Baazaoui N, Iqbal K. COVID-19 and neurodegenerative diseases: prion-like spread and long-term consequences. J Alzheimers Dis. (2022) 88:399&#x2013;416. 10.3233/JAD-220105</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-220105</ArticleId><ArticleId IdType="pubmed">35599487</ArticleId></ArticleIdList></Reference><Reference><Citation>Merello M, Bhatia KP, Obeso JA. SARS-CoV-2 and the risk of Parkinson's disease: facts and fantasy. Lancet Neurol. (2021) 20:94&#x2013;95. 10.1016/S1474-4422(20)30442-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30442-7</ArticleId><ArticleId IdType="pmc">PMC7834123</ArticleId><ArticleId IdType="pubmed">33253627</ArticleId></ArticleIdList></Reference><Reference><Citation>Awogbindin IO, Ben-Azu B, Olusola BA, Akinluyi ET, Adeniyi PA, Paolo TD, et al. . Microglial implications in SARS-CoV-2 infection and COVID-19: lessons from viral RNA neurotropism and possible relevance to Parkinson's Disease. Front Cell Neurosci. (2021) 15:670298. 10.3389/fncel.2021.670298</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.670298</ArticleId><ArticleId IdType="pmc">PMC8240959</ArticleId><ArticleId IdType="pubmed">34211370</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. (2018) 8:S3&#x2013;8. 10.3233/JPD-181474</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-181474</ArticleId><ArticleId IdType="pmc">PMC6311367</ArticleId><ArticleId IdType="pubmed">30584159</ArticleId></ArticleIdList></Reference><Reference><Citation>Massey D Baker AD Berrent DZ G&#xfc;the N Shidlovsky SP Fisher L . Internal tremors and vibration symptoms among people with postacute sequelae of SARS-CoV-2: a narrative review of patient reports. medRxiv. (2021) 12:12.03.21267146. 10.1101/2021.12.03.21267146</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.03.21267146</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, Weia H, Lowa RJ, Re'em Y, et al. . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. (2021) 38:101019. 10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf F, Fahriani M, Mamada SS, Frediansyah A, Abubakar A, Maghfirah D, et al. . Global prevalence of prolonged gastrointestinal symptoms in COVID-19 survivors and potential pathogenesis: a systematic review and meta-analysis. F1000Research. (2021) 10:301&#x2013;19. 10.12688/f1000research.52216.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.52216.1</ArticleId><ArticleId IdType="pmc">PMC8171196</ArticleId><ArticleId IdType="pubmed">34131481</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Shen Y, Li M, Chuang H, Ye Y, Zhao H, et al. . Clinical manifestations and evidence of neurological involvement in 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis. J Neurol. (2020) 267:2777&#x2013;89. 10.1007/s00415-020-09974-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09974-2</ArticleId><ArticleId IdType="pmc">PMC7288253</ArticleId><ArticleId IdType="pubmed">32529575</ArticleId></ArticleIdList></Reference><Reference><Citation>Favas TT, Dev P, Chaurasis RN, Chakravarty K, Mishra R, Joshi D, et al. . Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions. Neurological Sci. (2020) 41:3437&#x2013;70. 10.1007/s10072-020-04801-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04801-y</ArticleId><ArticleId IdType="pmc">PMC7577367</ArticleId><ArticleId IdType="pubmed">33089477</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JP, Watson CJ, Badenoch J, Cross B, ButlerM, Song J, et al. . Neurology and Neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives. J Neurol Neurosurg Psychiatry. (2021) 92:932&#x2013;41. 10.1136/jnnp-2021-326405</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-326405</ArticleId><ArticleId IdType="pubmed">34083395</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitalakumar D, Sharma A, Jumar A, Flora SJS. Neurological manifestations in COVID-19 patients: a meta-analysis. ACS Chem Neurosci. (2021) 12:2776&#x2013;97. 10.1021/acschemneuro.1c00353</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.1c00353</ArticleId><ArticleId IdType="pubmed">34260855</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassin A, Nawaiseh M, Shaban A, Alsherbini K, El-Salem K, Soudah O, et al. . Neurological manifestations and complications of coronavirus disease (2019) (COVID-19): a systematic review and meta-analysis. BMC Neurol. (2021) 21:138&#x2013;55. 10.1186/s12883-021-02161-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-021-02161-4</ArticleId><ArticleId IdType="pmc">PMC8007661</ArticleId><ArticleId IdType="pubmed">33784985</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardenas G, Soto-Hernandez JL, Diaz-Alba A, Ugalde Y, Merida-Puga J, Rosetti M, et al. . Neurological events related to influenza (H1N1) pdm09. Influenza Other Respir Viruses. (2014) 8:339&#x2013;46. 10.1111/irv.12241</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12241</ArticleId><ArticleId IdType="pmc">PMC4181482</ArticleId><ArticleId IdType="pubmed">24895698</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakkerMB. Long COVID or Post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. (2021) 12:698169. 10.3389/fmicb.2021.698169</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. . Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open. (2021) 4:210830. 10.1001/jamanetworkopen.2021.0830</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0830</ArticleId><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Sklinda K, Dorobek M, Wasilewski PG, Drezewski K, Debicka M, Walecki J, et al. . Radiological manifestation of neurological complications in the course of SARS-CoV-2 infection. Front Neurol. (2021) 12:711026. 10.3389/fneur.2021.711026</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.711026</ArticleId><ArticleId IdType="pmc">PMC8563625</ArticleId><ArticleId IdType="pubmed">34744963</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim PW, Kim M, Suh CH, Chung SR, Park JE, Kim SC, et al. . Neuroimaging findings in patients with COVID-19: a systematic review andmeta-analysis. Korean J Radiol. (2021) 22:1875&#x2013;85. 10.3348/kjr.2021.0127</Citation><ArticleIdList><ArticleId IdType="doi">10.3348/kjr.2021.0127</ArticleId><ArticleId IdType="pmc">PMC8546134</ArticleId><ArticleId IdType="pubmed">34269530</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi Y, Lee MK. Neuroimaging findings of brain MRI and CT in patients with COVID-19: a systematic review and meta-analysis. Eur J Radiol. (2020) 133. 109393. 10.1016/j.ejrad.2020.109393</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejrad.2020.109393</ArticleId><ArticleId IdType="pmc">PMC7606068</ArticleId><ArticleId IdType="pubmed">33161199</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MH, Perl DP, Nair G, Li W, Maric D, Murray H, et al. . Microvascular injury in the brains of patients with COVID-19. N Engl J Med. (2021) 384:481&#x2013;3. 10.1056/NEJMc2033369</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2033369</ArticleId><ArticleId IdType="pmc">PMC7787217</ArticleId><ArticleId IdType="pubmed">33378608</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis A, Frontera J, Placantonakis DG, Lighter J, Galetta S, Balcer L, et al. . Cerebrospinal fluid in COVID-19: a systematic review of the literature. J Neurol Sci. (2021). 10.1016/j.jns.2021.117316</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.117316</ArticleId><ArticleId IdType="pmc">PMC7833669</ArticleId><ArticleId IdType="pubmed">33561753</ArticleId></ArticleIdList></Reference><Reference><Citation>Matschke J, Lutgehetmann M, Hagel C, Sperhake JP, Schr&#xf6;der AS, Edler C, et al. . Neuropathology of patients with COVID-19 in Germany: a post-mortemcase series. Lancet Neurol. (2020) 19:919&#x2013;29. 10.1016/S1474-4422(20)30308-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30308-2</ArticleId><ArticleId IdType="pmc">PMC7535629</ArticleId><ArticleId IdType="pubmed">33031735</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanin L, Saraceno G, Panciani PP, Renisi G, Signorini L, Migliorati K, Fontanella MM. SARS-CoV-2 can induce brain and spine demyelinating lesions. Acta Neurochir. (2020) 162:1491&#x2013;4. 10.1007/s00701-020-04374-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00701-020-04374-x</ArticleId><ArticleId IdType="pmc">PMC7197630</ArticleId><ArticleId IdType="pubmed">32367205</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai JP, Baker AJ. Influenza-associated neurological complications. Neurocritical Care. (2013) 18:118&#x2013;30. 10.1007/s12028-012-9796-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12028-012-9796-8</ArticleId><ArticleId IdType="pubmed">23138546</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis LE, Koster F, Cawthon A. Neurologic aspects of influenza viruses. Handb Clin Neurol. (2014) 123:619&#x2013;45. 10.1016/B978-0-444-53488-0.00030-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-444-53488-0.00030-4</ArticleId><ArticleId IdType="pmc">PMC7152431</ArticleId><ArticleId IdType="pubmed">25015508</ArticleId></ArticleIdList></Reference><Reference><Citation>Akins PT, Belko J, Uyeki TM, Axelrod Y, Lee KK, Silverthorn J. H1N1 encephalitis with malignant edema and review of neurologic complications from influenza. Neurocrit Care. (2010) 13:396&#x2013;406. 10.1007/s12028-010-9436-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12028-010-9436-0</ArticleId><ArticleId IdType="pmc">PMC7100075</ArticleId><ArticleId IdType="pubmed">20811962</ArticleId></ArticleIdList></Reference><Reference><Citation>Macfarlane RG, Wroe SJ, Collinge J, Yousry TA, Jager HR. Neuroimaging findings in human prion disease. J Neurol Neurosurg Psychiatry. (2007) 78:664&#x2013;70. 10.1136/jnnp.2006.094821</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2006.094821</ArticleId><ArticleId IdType="pmc">PMC2117674</ArticleId><ArticleId IdType="pubmed">17135459</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragoso DC, Goncalves Filho AL, Pacheco FT, Barros BR, Littig IA, Nunes RH, et al. . Imaging of Creutzfeldt-Jakob disease: imaging patterns and their differential diagnosis. Radiographics. (2017) 37:234&#x2013;57. 10.1148/rg.2017160075</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/rg.2017160075</ArticleId><ArticleId IdType="pubmed">28076012</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquez F, YassaMA. Neuroimaging biomarkers for Alzheimer's disease. Mol Neurodegen. (2019) 14:21&#x2013;35. 10.1186/s13024-019-0325-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-019-0325-5</ArticleId><ArticleId IdType="pmc">PMC6555939</ArticleId><ArticleId IdType="pubmed">31174557</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchel T, Lehericy S, Chiu SY, Strafella AP, Stoessl AJ, Vaillancourt DE. Emerging neuroimaging biomarkers across disease stage in Parkinson's disease: a review. JAMA Neurol. (2021) 78:1262&#x2013;72. 10.1001/jamaneurol.2021.1312</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.1312</ArticleId><ArticleId IdType="pmc">PMC9017381</ArticleId><ArticleId IdType="pubmed">34459865</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed U, Lang AE, Masellis M. Neuroimaging advances in Parkinson's disease and atypical Parkinsonian syndromes. Front Neurol. (2020) 11:572976. 10.3389/fneur.2020.572976</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.572976</ArticleId><ArticleId IdType="pmc">PMC7593544</ArticleId><ArticleId IdType="pubmed">33178113</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadar M, Manera AL, Zinman L, Korngut L, Genge A, Graham SJ, et al. . Cerebral atrophy in amyotrophic lateral sclerosis parellels the pathological distribution of TDP43. Brain Commun. (2020) 2:fcaa061. 10.1093/braincomms/fcaa061</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa061</ArticleId><ArticleId IdType="pmc">PMC7846188</ArticleId><ArticleId IdType="pubmed">33543125</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazon M, Vazquez Costa JF, Ten-Esteve A, Mart&#xed;-Bonmat&#xed; L. Imaging biomarkers for the diagnosis and prognosis of neurodegenerative diseases. The example of amyotrophic lateral sclerosis. Front Neurosci. (2018) 12:784. 10.3389/fnins.2018.00784</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00784</ArticleId><ArticleId IdType="pmc">PMC6209630</ArticleId><ArticleId IdType="pubmed">30410433</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke RAL, Agosta F, Grosskreutz J, Filippi M, Turner MR. Neuroimaging endpoints in amyotrophic lateral sclerosis. Neurotherapeutics. (2017) 14:11&#x2013;23. 10.1007/s13311-016-0484-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0484-9</ArticleId><ArticleId IdType="pmc">PMC5233627</ArticleId><ArticleId IdType="pubmed">27752938</ArticleId></ArticleIdList></Reference><Reference><Citation>ACEP (American College of Emergency Physicians) . Available online at: https://www.acep.org/corona/covid-19-field-guide/assessment/laboratory-abnormalities (accessed February 23, 2022).</Citation></Reference><Reference><Citation>Meijer WJ, Linn FH, Wensing AM, Wensing AMJ, Leavis HL, van Riel D, et al. . Acute influenza virus-associated encephalitis and encephalopathy in adults: a challenging diagnosis. JMM Case Rep. (2016) 3:e005076. 10.1099/jmmcr.0.005076</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jmmcr.0.005076</ArticleId><ArticleId IdType="pmc">PMC5343125</ArticleId><ArticleId IdType="pubmed">28348797</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudge P, Hyare H, Green A, Collinge J, Mead S. Imaging and CSF analyses effectively distinguish CJD from its mimics. J Neurol Neurosurg Psychiatry. (2018) 89:461&#x2013;6. 10.1136/jnnp-2017-316853</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316853</ArticleId><ArticleId IdType="pmc">PMC5909756</ArticleId><ArticleId IdType="pubmed">29142140</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead S, Rudge P. CJD mimics and chameleons. Pract Neurol. (2017) 17:113&#x2013;21. 10.1136/practneurol-2016-001571</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/practneurol-2016-001571</ArticleId><ArticleId IdType="pmc">PMC5520355</ArticleId><ArticleId IdType="pubmed">28153848</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabelli C. Blood and cerebrospinal fluid biomarkers for Alzheimer's disease. J Lab Precis Med. (2020) 5:15. 10.21037/jlpm.2019.12.04</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jlpm.2019.12.04</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurbatova N, GargM, Whiley L, Chekmeneva E, Jim&#xe9;nez B, G&#xf3;mez-Romero M, et al. . Urinary metabolic phenotyping for Alzheimer's disease. Sci Rep. (2020) 10:21745. 10.1038/s41598-020-78031-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-78031-9</ArticleId><ArticleId IdType="pmc">PMC7730184</ArticleId><ArticleId IdType="pubmed">33303834</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, Tang H, Nie K, Wang L, Zhao J, Gan R, et al. . Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis. Int J Neurosci. (2015) 125:645&#x2013;54. 10.3109/00207454.2014.961454</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00207454.2014.961454</ArticleId><ArticleId IdType="pubmed">25202803</ArticleId></ArticleIdList></Reference><Reference><Citation>Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, et al. . CSF and blood biomarkers for Parkinson's disease. Lancet Neurol. (2019) 18:573&#x2013;86. 10.1016/S1474-4422(19)30024-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30024-9</ArticleId><ArticleId IdType="pubmed">30981640</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder V, Gregory JM, Barria MA, Green A, Pal S. TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. BMC Neurol. (2018) 18:90. 10.1186/s12883-018-1091-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-018-1091-7</ArticleId><ArticleId IdType="pmc">PMC6027783</ArticleId><ArticleId IdType="pubmed">29954341</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M. Eletrodiagnosis of Amyotrophic lateral sclerosis: a review of existing guidelines. J Clin Neurophysiol. (2020) 37:294&#x2013;8. 10.1097/WNP.0000000000000682</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNP.0000000000000682</ArticleId><ArticleId IdType="pubmed">33151660</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima N, Sato Y, Katano H, Hasegawa H, Kumasaka T, Hata S, et al. . Histopathological and immunohistochemical findings of 20 autopsy cases with (2009) H1N1 virus infection. Mod Pathol. (2012) 25:1&#x2013;3. 10.1038/modpathol.2011.180</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/modpathol.2011.180</ArticleId><ArticleId IdType="pubmed">21874012</ArticleId></ArticleIdList></Reference><Reference><Citation>DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. Mol Neurodegen. (2019) 14:32. 10.1186/s13024-019-0333-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-019-0333-5</ArticleId><ArticleId IdType="pmc">PMC6679484</ArticleId><ArticleId IdType="pubmed">31375134</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S, Stauffer JE, Schulte DJ, Ravits J. Neuropathology of amyotrophic lateral sclerosis and its variants. Neurol Clin. (2015) 33:855&#x2013;76. 10.1016/j.ncl.2015.07.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.012</ArticleId><ArticleId IdType="pmc">PMC4628785</ArticleId><ArticleId IdType="pubmed">26515626</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Budka H. Molecular pathology of human prion diseases. Int J Mol Sci. (2009) 10:976&#x2013;99. 10.3390/ijms10030976</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms10030976</ArticleId><ArticleId IdType="pmc">PMC2672014</ArticleId><ArticleId IdType="pubmed">19399233</ArticleId></ArticleIdList></Reference><Reference><Citation>Geut H, Hepp DH, Foncke E, Berendse HW, Rozemuller JM, Huitinga I, et al. . Neuropathological correlates of parkinsonian disorders in a large Dutch autopsy series. Acta Neuropathol Communic. (2020) 8:39&#x2013;53. 10.1186/s40478-020-00914-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-00914-9</ArticleId><ArticleId IdType="pmc">PMC7098103</ArticleId><ArticleId IdType="pubmed">32216828</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandao PRP, Grippe TC, Pereira DA, Munhoz RP, Cardoso F. New-onset movement disorders associated with COVID-19. Tremor Other Hyperkinetic Mov. (2021) 11:1&#x2013;17. 10.5334/tohm.595</Citation><ArticleIdList><ArticleId IdType="doi">10.5334/tohm.595</ArticleId><ArticleId IdType="pmc">PMC8269765</ArticleId><ArticleId IdType="pubmed">34277139</ArticleId></ArticleIdList></Reference><Reference><Citation>Oppo V, Melis M, Melis M, Barbarossa LT, Cossu G. &#x201c;Smelling and Tasting&#x201d; Parkinson's disease: using senses to improve the knowledge of the disease. Front Aging Neurosci. (2020) 12:43. 10.3389/fnagi.2020.00043</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2020.00043</ArticleId><ArticleId IdType="pmc">PMC7052524</ArticleId><ArticleId IdType="pubmed">32161534</ArticleId></ArticleIdList></Reference><Reference><Citation>Valerio F, Whitehouse DP, Menon DK, Newcombe VFJ. The neurological sequelae of pandemics and epidemics. J Neurol. (2021) 268:2629. 10.1007/s00415-020-10261-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10261-3</ArticleId><ArticleId IdType="pmc">PMC7587542</ArticleId><ArticleId IdType="pubmed">33106890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan D, Du T, Hong W, Chen L, Que H, Lu S, et al. . Neurological complications and infection mechanism of SARS-CoV-2. Sig Transduct Target Ther. (2021) 6:406&#x2013;22. 10.1038/s41392-021-00818-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00818-7</ArticleId><ArticleId IdType="pmc">PMC8609271</ArticleId><ArticleId IdType="pubmed">34815399</ArticleId></ArticleIdList></Reference><Reference><Citation>Balcom EF, Nath A, Power C. Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease. Brain. (2021) 144:3576&#x2013;88. 10.1093/brain/awab302</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab302</ArticleId><ArticleId IdType="pmc">PMC8719840</ArticleId><ArticleId IdType="pubmed">34398188</ArticleId></ArticleIdList></Reference><Reference><Citation>Gracia-Ramos AE, Martin-Nares E, Hernandez-Molina G. New onset of autoimmune diseases following COVID-19 diagnosis. Cells. (2021) 10:3592. 10.3390/cells10123592</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10123592</ArticleId><ArticleId IdType="pmc">PMC8700122</ArticleId><ArticleId IdType="pubmed">34944099</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan RK, Kashour T, Hamid Q, Halwani R, Tleyjeh IM. Unraveling the mystery surrounding post-acute sequelae of COVID-19. Front Immunol. (2021) 12:686029. 10.3389/fimmu.2021.686029</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.686029</ArticleId><ArticleId IdType="pmc">PMC8278217</ArticleId><ArticleId IdType="pubmed">34276671</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohmwald K, Galvez MNS, Rios M, Kalergis AM. Neurologic alterations due to respiratory virus infections. Front Cell Neurosci. (2018) 12:386. 10.3389/fncel.2018.00386</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00386</ArticleId><ArticleId IdType="pmc">PMC6212673</ArticleId><ArticleId IdType="pubmed">30416428</ArticleId></ArticleIdList></Reference><Reference><Citation>Saa P, Harris DA, Cervenakova L. Mechanisms of prion-induced neurodegeneration. Expert Rev Mol Med. (2016) 18:e5. 10.1017/erm.2016.8</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/erm.2016.8</ArticleId><ArticleId IdType="pubmed">27055367</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Xu F, Nie Z, Shao L. Gut microbiota approach&#x2014;a new strategy to treat Parkinson's disease. Front Cell Infect Microbiol. (2021) 10:570658. 10.3389/fcimb.2020.570658</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.570658</ArticleId><ArticleId IdType="pmc">PMC7643014</ArticleId><ArticleId IdType="pubmed">33194809</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz-Hernandez M, Barritt JD, Sobek J, Hornemannc S, Aguzzic A, Simone AD. Mechanism of misfolding of the human prion protein revealed by a pathological mutation. Proc Natl Acad Sci USA. (2021) 118:e2019631118. 10.1073/pnas.2019631118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2019631118</ArticleId><ArticleId IdType="pmc">PMC7999870</ArticleId><ArticleId IdType="pubmed">33731477</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Sommerville NR, Liu JYH, Ngan MP, Poon D, Ponomarev ED, et al. . Intra-gastrointestinal amyloid-beta1&#x2013;42 oligomers perturb enteric function and induce Alzheimer's disease pathology. J Physiol. (2020) 598:4209&#x2013;23. 10.1113/JP279919</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP279919</ArticleId><ArticleId IdType="pmc">PMC7586845</ArticleId><ArticleId IdType="pubmed">32617993</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, et al. . Porphyromonas gingivalis in Alzheimer's disease brains: evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv. (2019) 5:eaau3333. 10.1126/sciadv.aau3333</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aau3333</ArticleId><ArticleId IdType="pmc">PMC6357742</ArticleId><ArticleId IdType="pubmed">30746447</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin WS, Di J, Cao Q, Li B, Seidler PM, Murray KA, et al. . Amyloid-beta protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation. Alz Res Ther. (2019) 11:86. 10.1186/s13195-019-0541-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0541-9</ArticleId><ArticleId IdType="pmc">PMC6800506</ArticleId><ArticleId IdType="pubmed">31627745</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Zhang D, Zehng Y, Huang TY, Xu H, Zhao Y. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. Mol Neurodegen. (2020) 15:40. 10.1186/s13024-020-00391-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00391-7</ArticleId><ArticleId IdType="pmc">PMC7364557</ArticleId><ArticleId IdType="pubmed">32677986</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald E, Murphy S, Martinson HA. Alpha-synuclein pathology and the role of the microbiota in Parkinson's disease. Front Neurosci. (2019) 13:369. 10.3389/fnins.2019.00369</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00369</ArticleId><ArticleId IdType="pmc">PMC6491838</ArticleId><ArticleId IdType="pubmed">31068777</ArticleId></ArticleIdList></Reference><Reference><Citation>Garretti F, Agalliu D, Lindestam Arlehamn CS, Sette A, Sulzer D. Autoimmunity in Parkinson's disease: the role of alpha-synuclein-specific T cells. Front Immunol. (2019) 10:303. 10.3389/fimmu.2019.00303</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00303</ArticleId><ArticleId IdType="pmc">PMC6397885</ArticleId><ArticleId IdType="pubmed">30858851</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiti P, Manna J, Dunbar GL. Current understanding of the molecular mechanisms in Parkinson's disease: targets for potential treatments. Transl Neurodegener. (2017) 6:28&#x2013;63. 10.1186/s40035-017-0099-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-017-0099-z</ArticleId><ArticleId IdType="pmc">PMC5655877</ArticleId><ArticleId IdType="pubmed">29090092</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue YC, Ruller CM, Fung G, Mohamud Y, Deng H, Liu H, et al. . Enteroviral infection leads to transactive response DNA-binding protein 43 pathology in vivo. Immunopathol Infect Dis. (2018) 188:2853&#x2013;62. 10.1016/j.ajpath.2018.08.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2018.08.013</ArticleId><ArticleId IdType="pubmed">30273599</ArticleId></ArticleIdList></Reference><Reference><Citation>Doubille RN, Nath A. Human endogenous retrovirus-K and TDP-43 expression bridges ALS and HIV neuropathology. Front Microbil. (2017) 8:1986. 10.3389/fmicb.2017.01986</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.01986</ArticleId><ArticleId IdType="pmc">PMC5641584</ArticleId><ArticleId IdType="pubmed">29075249</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari AP. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. (2019) 13:1310. 10.3389/fnins.2019.01310</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Yachou Y, Idrissi AE, Belapasov V, Benali SA. Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients. Neurol Sci. (2020) 28:1&#x2013;13. 10.1007/s10072-020-04575-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04575-3</ArticleId><ArticleId IdType="pmc">PMC7385206</ArticleId><ArticleId IdType="pubmed">32725449</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra R, Banerjea AC. Neurological damage by coronaviruses: a catastrophe in the queue! Front Immunol. (2020) 11:565521. 10.3389/fimmu.2020.565521</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.565521</ArticleId><ArticleId IdType="pmc">PMC7511585</ArticleId><ArticleId IdType="pubmed">33013930</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Liu T, Yang N, Han D, Mi X, Li Y, et al. . Neurological manifestations of patients with COVID-19: potential routes of SARS-CoV-2 neuroinvasion from the periphery to the brain. Front Med. (2020) 14:533&#x2013;41. 10.1007/s11684-020-0786-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-020-0786-5</ArticleId><ArticleId IdType="pmc">PMC7197033</ArticleId><ArticleId IdType="pubmed">32367431</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. . Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. (2022) 185:881&#x2013;95.e20. 10.1016/j.cell.2022.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng XS, Geng WS, Jia JJ, Chen L, Zhang P. Cellular and molecular basis of neurodegeneration in Parkinson's disease. Front Aging Neurosci. (2018) 10:109&#x2013;25. 10.3389/fnagi.2018.00109</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2018.00109</ArticleId><ArticleId IdType="pmc">PMC5913322</ArticleId><ArticleId IdType="pubmed">29719505</ArticleId></ArticleIdList></Reference><Reference><Citation>Ubeda-Banon I, Saiz-Sanchez D, dela Rosa-Prieto C, Martinez-Marcos A. Alpha-synuclein in the olfactory system in Parkinson's disease: role of neural connections on spreading pathology. Brain Struct Funct. (2014) 219:1513&#x2013;26. 10.1007/s00429-013-0651-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00429-013-0651-2</ArticleId><ArticleId IdType="pubmed">24135772</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. (2003) 110:517&#x2013;36. 10.1007/s00702-002-0808-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-002-0808-2</ArticleId><ArticleId IdType="pubmed">12721813</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K, Rub U, de Vos RAI, Steur ENHJ, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. (2003) 24:197&#x2013;211. 10.1016/S0197-4580(02)00065-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(02)00065-9</ArticleId><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Gao J, Wang J. Prion-like mechanisms in Parkinson's disease. Front Neurosci. (2019) 13:552. 10.3389/fnins.2019.00552</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00552</ArticleId><ArticleId IdType="pmc">PMC6591488</ArticleId><ArticleId IdType="pubmed">31275093</ArticleId></ArticleIdList></Reference><Reference><Citation>Jana AK, Lander CW, Cheney AD, Hansmann UHE. Effect of an amyloidogenic SARS-CoV-2 protein fragment on alpha-synuclein monomers and fibrils. bioRxiv. (2022) 2:02.21.481360. 10.1101/2022.02.21.481360</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.21.481360</ArticleId><ArticleId IdType="pmc">PMC9186263</ArticleId><ArticleId IdType="pubmed">35580331</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavel A, Murray DK, Stoessl AJ. COVID-19 and selective vulnerability of Parkinson's disease. Lancet Neurol. (2020) 19:719. 10.1016/S1474-4422(20)30269-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30269-6</ArticleId><ArticleId IdType="pmc">PMC7434474</ArticleId><ArticleId IdType="pubmed">32822628</ArticleId></ArticleIdList></Reference><Reference><Citation>Idrees D, Kumar V. SARS-CoV-2 spike protein interactions with amyloidogenic proteins: potential clues to neurodegeneration. Biochem Biophys Res Commun. (2021) 554:94&#x2013;8. 10.1016/j.bbrc.2021.03.100</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2021.03.100</ArticleId><ArticleId IdType="pmc">PMC7988450</ArticleId><ArticleId IdType="pubmed">33789211</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Zhang X, Huang Z, Ma K. SARS-CoV-2 proteins interact with alpha synuclein and induce Lewy Body-like pathology in vitro. Int J Mol Sci. (2022) 23:3394. 10.3390/ijms23063394</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23063394</ArticleId><ArticleId IdType="pmc">PMC8949667</ArticleId><ArticleId IdType="pubmed">35328814</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan&#xe1;-Cuevas P, Salles-G&#xe1;ndara P, Rojas-Fernandez A, Salinas-Rebolledo C, Mil&#xe1;n-Sol&#xe9; A. The potential role of SARS-CoV-2 in the pathogenesis of Parkinson's disease. Front Neurol. (2020) 11:1044. 10.3389/fneur.2020.01044</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.01044</ArticleId><ArticleId IdType="pmc">PMC7527541</ArticleId><ArticleId IdType="pubmed">33041985</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabo MP, Iba M, Nath A, Masliah E, Kim C. Does SARS-CoV-2 affect neurodegenerative disorders? TLR2, a potential receptor for SARS-CoV-2 in the CNS. Exp Mol Med. (2022) 54:447&#x2013;54. 10.1038/s12276-022-00755-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-022-00755-7</ArticleId><ArticleId IdType="pmc">PMC8990637</ArticleId><ArticleId IdType="pubmed">35396576</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadasivan S, Sharp, B, Stacey SC, Smeyne RJ. Synergistic effects of influenza and 1-methyl-4-phenyl-1,2,3,6-tetrapydropyridine (MPTP) can be eliminated by the use of influenza therapeutics: experimental evidence for the multi-hit hypothesis. Npj Parkinsons Dis. (2017) 3:18. 10.1038/s41531-017-0019-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-017-0019-z</ArticleId><ArticleId IdType="pmc">PMC5460228</ArticleId><ArticleId IdType="pubmed">28649618</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravitz L. The promise and potential of stem cells in Parkinson's disease. Nature. (2021) 597:S8&#x2013;10. 10.1038/d41586-021-02622-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-02622-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Cushman M, Johnson BS, King OD, Gitler AD, Shorter J. Prion-like disorders: blurring the divide between transmissibility and infectivity. J Cell Sci. (2010) 123:1191&#x2013;201. 10.1242/jcs.051672</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.051672</ArticleId><ArticleId IdType="pmc">PMC2848109</ArticleId><ArticleId IdType="pubmed">20356930</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. NEURODEGENERATION. Alzheimer's and Parkinson's diseases: the prion concept in relation to assembled Ab, tau, and a-synuclein. Science. (2015) 349:1255555. 10.1126/science.1255555</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1255555</ArticleId><ArticleId IdType="pubmed">26250687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Kim HJ. Prion-like mechanism in amyotrophic lateral sclerosis: are protein aggregates the key? Exp Neurobiol. (2015) 24:1&#x2013;7. 10.5607/en.2015.24.1.1</Citation><ArticleIdList><ArticleId IdType="doi">10.5607/en.2015.24.1.1</ArticleId><ArticleId IdType="pmc">PMC4363329</ArticleId><ArticleId IdType="pubmed">25792864</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu XL, Li WW, Wang YJ. Is Alzheimer's Disease transmissible in humans? Neurosci Bull. (2019) 35:1113&#x2013;5. 10.1007/s12264-019-00382-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-019-00382-9</ArticleId><ArticleId IdType="pmc">PMC6864016</ArticleId><ArticleId IdType="pubmed">31037579</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomzig A, Wagenfuhr K, Pinder P, Joncic M, Schulz-Schaeffer WJ, Beekes M. Transmissible alpha-synuclein seeding activity in brain and stomach of patients with Parkinson's disease. Acta Neuropathol. (2021) 141:861&#x2013;79. 10.1007/s00401-021-02312-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02312-4</ArticleId><ArticleId IdType="pmc">PMC8068459</ArticleId><ArticleId IdType="pubmed">33895878</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam S, Petit F, Herard, AS, Boluda S, Eddarkaoui S, et al. . Transmission of amyloid-beta and tau pathologies is associated with cognitive impairments in a primate. Acta Neuropathol Commun. (2021) 9:165. 10.1186/s40478-021-01266-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-021-01266-8</ArticleId><ArticleId IdType="pmc">PMC8507137</ArticleId><ArticleId IdType="pubmed">34641980</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding X, Xiang Z, Qin C, Yongkang Chen, Haiyan Tian, Lin Meng, et al. . Spreading of TDP-43 pathology via pyramidal tract induces ALS-like phenotypesin TDP-43 transgenic mice. Acta Neuropathol Commun. (2021) 9:15. 10.1186/s40478-020-01112-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-01112-3</ArticleId><ArticleId IdType="pmc">PMC7814549</ArticleId><ArticleId IdType="pubmed">33461623</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaunmuktane Z, Mead S, Ellis M, Wadsworth JDF, Nicoll AJ, Kenny J, et al. . Evidence for human transmission of amyloid-beta pathology and cerebral amyloid angiopathy. Nature. (2015) 525:247&#x2013;50. 10.1038/nature15369</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature15369</ArticleId><ArticleId IdType="pubmed">26354483</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, et al. . Prion-like spreading of pathological alpha-synuclein in brain. Brain. (2013) 136:1128&#x2013;38. 10.1093/brain/awt037</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt037</ArticleId><ArticleId IdType="pmc">PMC3613715</ArticleId><ArticleId IdType="pubmed">23466394</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Eisenberg DS, Crowther RA. Propagation of Tau aggregates and neurodegeneration. Annu Rev Neurosci. (2017) 40:189&#x2013;210. 10.1146/annurev-neuro-072116-031153</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-072116-031153</ArticleId><ArticleId IdType="pubmed">28772101</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts JC, Giles K, Oehler A, Middleton L, Dexter DT, Gentleman SM, et al. . Transmission ofmultiple systematrophy prions to transgenicmice. Proc Natl Acad Sci USA. (2013) 110:19555&#x2013;60. 10.1073/pnas.1318268110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318268110</ArticleId><ArticleId IdType="pmc">PMC3845125</ArticleId><ArticleId IdType="pubmed">24218576</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson GA, Prusiner SB. How an infection of sheep revealed prion mechanisms in Alzheimer's Disease and other neurodegenerative disorders. Int J Mol Sci. (2021) 22:4861&#x2013;83. 10.3390/ijms22094861</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22094861</ArticleId><ArticleId IdType="pmc">PMC8125442</ArticleId><ArticleId IdType="pubmed">34064393</ArticleId></ArticleIdList></Reference><Reference><Citation>Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, et al. . The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS ONE. (2010) 5:e9505. 10.1371/journal.pone.0009505</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0009505</ArticleId><ArticleId IdType="pmc">PMC2831066</ArticleId><ArticleId IdType="pubmed">20209079</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatman EL, Massey A, Shives KD, Burrack KS, Chamanian M, Morrison TE, et al. . Alpha-synuclein expression restricts RNA viral infections in the brain. J Virol. (2015) 90:2767&#x2013;82. 10.1128/JVI.02949-15</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02949-15</ArticleId><ArticleId IdType="pmc">PMC4810656</ArticleId><ArticleId IdType="pubmed">26719256</ArticleId></ArticleIdList></Reference><Reference><Citation>Harms AS, Thome AD, Yan Z, Schonhoff AM, Williams GP, Li X, et al. . Peripheral monocyte entry is required for alpha-synuclein induced inflammation and neurodegeneration in a model of Parkinson disease. Exp Neurol. (2018) 300:179&#x2013;87. 10.1016/j.expneurol.2017.11.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2017.11.010</ArticleId><ArticleId IdType="pmc">PMC5759972</ArticleId><ArticleId IdType="pubmed">29155051</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner A, Chua SW, Berta J, Volkerling A, van der Hoven J, Gladbach A, et al. . Site-specific phosphorylation of tau inhibits amyloid-beta toxicity in Alzheimer's mice. Science. (2016) 354:904&#x2013;8. 10.1126/science.aah6205</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aah6205</ArticleId><ArticleId IdType="pubmed">27856911</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Wang Z, Liu L, Yanga Z, Liua S, Ma Z, et al. . LncRNA Malat1 inhibition of TDP-43 cleavage suppresses IRF3-initiated antiviral innate immunity. Proc Natl Acad Sci USA. (2020) 117:23695&#x2013;706. 10.1073/pnas.2003932117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2003932117</ArticleId><ArticleId IdType="pmc">PMC7519350</ArticleId><ArticleId IdType="pubmed">32907941</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue YC, Liu H, Mohamud Y, Bahreyni A, Zhang J, Cashman NR, et al. . Sublethal enteroviral infection exacerbates disease progression in an ALS mouse model. J Neuroinflamm. (2022) 19:16&#x2013;31. 10.1186/s12974-022-02380-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-022-02380-7</ArticleId><ArticleId IdType="pmc">PMC8753920</ArticleId><ArticleId IdType="pubmed">35022041</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz-Pinto MF, Empadinhas N, Cardoso SM. The neuromicrobiology of Parkinson's disease: a unifying theory. Aging Res Rev. (2021) 70:101396. 10.1016/j.arr.2021.101396</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2021.101396</ArticleId><ArticleId IdType="pubmed">34171417</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh TS, Chong CW, L Shen-Yang, Shao L. Gut microbiome in Parkinson's disease: new insights from meta-analysis. Parkinson Relat Disord. (2022) 94:1&#x2013;9. 10.1016/j.parkreldis.2021.11.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2021.11.017</ArticleId><ArticleId IdType="pubmed">34844021</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacher E Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M, et al. . Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. (2019) 572:474&#x2013;80. 10.1038/s41586-019-1443-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1443-5</ArticleId><ArticleId IdType="pubmed">31330533</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Argenio V, Sarnataro D. Microbiome influence in the pathogenesis of prion and Alzheimer's diseases. Int J Mol Sci. (2019) 20:4704. 10.3390/ijms20194704</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20194704</ArticleId><ArticleId IdType="pmc">PMC6801937</ArticleId><ArticleId IdType="pubmed">31547531</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim B, Prassas I, Diamandis EP. Alzheimer disease pathogenesis: the role of autoimmunity. J Applied Lab Med. (2021) 6:756&#x2013;764. 10.1093/jalm/jfaa171</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jalm/jfaa171</ArticleId><ArticleId IdType="pubmed">33241314</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonam SR, Muller S. Parkinson's disease is an autoimmune disease: a reappraisal. Autoimmune Rev. (2020) 19:102684. 10.1016/j.autrev.2020.102684</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102684</ArticleId><ArticleId IdType="pubmed">33131704</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani MF, Gonzalez LE, Uchitel OD. Autoimmunity in amyotrophic lateral sclerosis: past and present. Neurol Res Int. (2011) 2011:497080. 10.1155/2011/497080</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/497080</ArticleId><ArticleId IdType="pmc">PMC3150148</ArticleId><ArticleId IdType="pubmed">21826267</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu BT. Human and animal spongiform encephalopathies are the result of chronic autoimmune attack in the CNS: a novel medical theory supported by overwhelming experimental evidence. Hostol Histopathol. (2005) 20:575&#x2013;92. 10.14670/HH-20.575</Citation><ArticleIdList><ArticleId IdType="doi">10.14670/HH-20.575</ArticleId><ArticleId IdType="pubmed">15736062</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. (1991) 82:239&#x2013;59. 10.1007/BF00308809</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmer H, Tredici KD. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. (2006) 112:389&#x2013;404. 10.1007/s00401-006-0127-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0127-z</ArticleId><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Rietdijk CD, Perez-Pardo P, Garssen J, van Wezel RJA, Kraneveld AD. Exploring Braak's hypothesis of Parkinson's disease. Front Neurol. (2017) 8:37. 10.3389/fneur.2017.00037</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00037</ArticleId><ArticleId IdType="pmc">PMC5304413</ArticleId><ArticleId IdType="pubmed">28243222</ArticleId></ArticleIdList></Reference><Reference><Citation>Biel D, Brendel M, Rubinski A, Buerger K, Janowitz D, Dichgans M, et al. . Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. Alz Res Ther. (2021) 13:137. 10.1186/s13195-021-00880-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-021-00880-x</ArticleId><ArticleId IdType="pmc">PMC8361801</ArticleId><ArticleId IdType="pubmed">34384484</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, Jaglin JA, et al. . Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord. (2012) 27:709&#x2013;15. 10.1002/mds.23838</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23838</ArticleId><ArticleId IdType="pubmed">21766334</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Fujishiro H, DelleDonne A, Menka J, Ahmed Z, Klos KJ, et al. . Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol. (2008) 115:437&#x2013;44. 10.1007/s00401-008-0345-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0345-7</ArticleId><ArticleId IdType="pubmed">18264713</ArticleId></ArticleIdList></Reference><Reference><Citation>Marreiros R, Muller-Schiffmann A, Trossbach SV, Prikulisa I, H&#xe4;nschb S, Weidtkamp-Peters S, et al. . Disruption of cellular proteostasis by H1N1 influenza A virus causes alpha-synuclein aggregation. Proc Natl Acad Sci USA. (2020) 117:6741&#x2013;51. 10.1073/pnas.1906466117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1906466117</ArticleId><ArticleId IdType="pmc">PMC7104400</ArticleId><ArticleId IdType="pubmed">32152117</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindman KL, Hemmingsson ES, Weidung B, Br&#xe4;nnstr&#xf6;m J, Josefsson M, Olsson J, et al. . Herpesvirus infections, antiviral treatment, and the risk of dementia registry-based cohort study in Sweden. Alzhe Dement Transl Res Clin Interv. (2021) 7:e12119. 10.1002/trc2.12119</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/trc2.12119</ArticleId><ArticleId IdType="pmc">PMC7882534</ArticleId><ArticleId IdType="pubmed">33614892</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainberg M, Luquez T, Koelle DM, Readhead B, Johnston C, Darvas M, et al. . The viral hypothesis: how herpesviruses may contribute to Alzheimer's disease. Mol Psychiatry. (2021) 26:5476&#x2013;80. 10.1038/s41380-021-01138-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01138-6</ArticleId><ArticleId IdType="pmc">PMC8758477</ArticleId><ArticleId IdType="pubmed">33972690</ArticleId></ArticleIdList></Reference><Reference><Citation>Caggiu E, Arru G, Hosseini S, Niegowska M, Sechi G, Zarbo IR, et al. . Inflammation, infectious triggers and Parkinson's disease. Front Neurol. (2019) 10:122. 10.3389/fneur.2019.00122</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00122</ArticleId><ArticleId IdType="pmc">PMC6389614</ArticleId><ArticleId IdType="pubmed">30837941</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib AG, Yakasai AM, Owolabi LF, Ibrahim A, Habib ZG, Gudaji M, et al. . Neurocognitive impairment in HIV-1-infected adults in Sub-Saharan Africa: a systematic review and meta-analysis. Int J Infect Dis. (2013) 17:820&#x2013;31. 10.1016/j.ijid.2013.06.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2013.06.011</ArticleId><ArticleId IdType="pubmed">23953699</ArticleId></ArticleIdList></Reference><Reference><Citation>Maschke M, Kastrup O, Esser S, Ross B, Hengge U, Hufnagel A. Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatry. (2000) 69:376&#x2013;80. 10.1136/jnnp.69.3.376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.69.3.376</ArticleId><ArticleId IdType="pmc">PMC1737101</ArticleId><ArticleId IdType="pubmed">10945813</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng YW, Lin CH, Wu RM. HIV-associated parkinsonism reversed with antiretroviral therapy. Reurol Asia. (2014) 19:199&#x2013;203.</Citation></Reference><Reference><Citation>Beingpatient.com. Available online at: https://www.beingpatient.com/there-are-9-alzheimers-vaccines-in-trials-right-now/ (assessed February 20, 2022).</Citation></Reference><Reference><Citation>Soeda Y and Takashima A . New insights into drug discovery targeting tau protein. Front Mol Neurosci. (2020) 13:590896. 10.3389/fnmol.2020.5.90896</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2020.5.90896</ArticleId><ArticleId IdType="pmc">PMC7744460</ArticleId><ArticleId IdType="pubmed">33343298</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbut D, Stolzenberg E, Zasloff M. Gastrointestinal immunity and alphasynuclein. J Parkinsons Dis. (2019) 9:313&#x2013;22. 10.3233/JPD-191702</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-191702</ArticleId><ArticleId IdType="pmc">PMC6839499</ArticleId><ArticleId IdType="pubmed">31594249</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamal F. Immunotherapies targeting alpha-synuclein in Parkinson disease. Fec Pract. (2020) 37:375&#x2013;9. 10.12788/fp.0026</Citation><ArticleIdList><ArticleId IdType="doi">10.12788/fp.0026</ArticleId><ArticleId IdType="pmc">PMC7473734</ArticleId><ArticleId IdType="pubmed">32908345</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming SM, Davis, A, Simons E. Targeting alpha-synuclein via the immune system in Parkinson's disease: current vaccine therapies. Neuropharmacology. (2022) 202:108870. 10.1016/j.neuropharm.2021.108870</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2021.108870</ArticleId><ArticleId IdType="pmc">PMC10251253</ArticleId><ArticleId IdType="pubmed">34742741</ArticleId></ArticleIdList></Reference><Reference><Citation>Cragnaz L, Spinelli G, Conti LD, Bureau EA, Brownlees J, Feiguin F, et al. . Thioridazine reverts the phenotype in cellular and Drosophila models of amyotrophic lateral sclerosis by enhancing TDP-43 aggregate clearance. Neurobiol Dis. (2021) 160:105515. 10.1016/j.nbd.2021.105515</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2021.105515</ArticleId><ArticleId IdType="pubmed">34571136</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortada I, Farah R, Nabha S, Ojcius DM, Fares Y, Almawi WY, et al. . Immunotherapies for neurodegenerative diseases. Front Neurol. (2021) 12:654739. 10.3389/fneur.2021.654739</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.654739</ArticleId><ArticleId IdType="pmc">PMC8215715</ArticleId><ArticleId IdType="pubmed">34163421</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>